OTCMKTS:ABVC

ABVC BioPharma Stock Forecast, Price & News

$4.94

+0.54 (+12.27 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.85

▼

$4.99

50-Day Range

$4.40

▼

$5.55

52-Week Range

$2.75

▼

$8.00

Volume571 shs

Average Volume719 shs

Market Capitalization$131.85 million

P/E RatioN/A

Dividend YieldN/A

Beta0.51

30 days | 90 days | 365 days | Advanced Chart

Receive ABVC News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

About ABVC BioPharma

American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.

ABVC: Enhancing Financial Flexibility To Support Growth Strategy
June 9, 2021 | finance.yahoo.com

ADHD Drugs Market | Global size is growing with CAGR of 8.7% and expected to reach ~ US$ 3.5 BN by 2026
April 24, 2021 | marketwatch.com

ABVC: Developing a Growing Portfolio Of Plant-Based Therapies With Strong Prospects
January 27, 2021 | finance.yahoo.com

American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021
January 6, 2021 | finance.yahoo.com

News for American BriVision Holding Corp Registered Shs
December 24, 2020 | markets.businessinsider.com

American BriVision Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
November 9, 2020 | finance.yahoo.com

American BriVision Issues Clinical Study Report for Vitargus First-in-Human Phase I Clinical Trial
September 9, 2020 | finance.yahoo.com

American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder
August 24, 2020 | finance.yahoo.com

Biotech Incubator Trades At 6-Month High, Lead Medical Device A Game Changer
August 5, 2020 | baystreet.ca

WNBA players wearing T-shirts opposing Dream owner
August 5, 2020 | abcnews.go.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ABVC
Previous Symbol
CUSIPN/A
CIK1173313
Webwww.ambrivis.com
Phone845-291-1291
Employees30
Year FoundedN/A

Sales & Book Value

Annual Sales$480,000.00
Price / Sales274.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.11 per share
Price / Book44.91

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-9,790,000.00
Net Margins-1,448.64%
Return on Equity-2,077.26%
Return on Assets-103.88%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares26,690,000
Market Cap$131.85 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.05 out of 5 stars

Medical Sector

1262nd out of 2,222 stocks

Pharmaceutical Preparations Industry

588th out of 869 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for ABVC BioPharma.

3.6 Community Rank

Outperform Votes
ABVC BioPharma has received 45 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ABVC BioPharma has received 18 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ABVC BioPharma has received 71.43% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ABVC BioPharma and other stocks. Vote “Outperform” if you believe ABVC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABVC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ABVC BioPharma does not currently pay a dividend.
Dividend Growth
ABVC BioPharma does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
49.60% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0 Earnings and Valuation

Earnings Growth
Earnings for ABVC BioPharma are expected to decrease in the coming year, from ($0.19) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ABVC BioPharma is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ABVC BioPharma is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ABVC BioPharma has a P/B Ratio of 44.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

ABVC BioPharma (OTCMKTS:ABVC) Frequently Asked Questions

What stocks does MarketBeat like better than ABVC BioPharma?

Wall Street analysts have given ABVC BioPharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ABVC BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has ABVC BioPharma's stock price been impacted by Coronavirus (COVID-19)?

ABVC BioPharma's stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABVC stock has increased by 70.3% and is now trading at $4.94.
View which stocks have been most impacted by COVID-19.

Who are ABVC BioPharma's key executives?

ABVC BioPharma's management team includes the following people:

Mr. Eugene Jiang, Chairman & Chief Bus. Officer (Age 35, Pay $200k)
Dr. Howard Doong M.D., Ph.D., Pres & CEO (Age 64, Pay $200k)
Mr. Chihliang An, Chief Financial Officer (Age 39, Pay $200k)
Dr. Chi-Hsin King, Chief Scientific Officer (Age 73, Pay $200k)
Dr. Tsung-Shann Jiang Ph.D., Chief Strategy Officer, Member of Scientific Advisory Board & Director (Age 67, Pay $200k)

Who are some of ABVC BioPharma's key competitors?

Some companies that are related to ABVC BioPharma include Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX), AC Immune (ACIU), VistaGen Therapeutics (VTGN), Greenwich LifeSciences (GLSI), Inventiva (IVA), Clovis Oncology (CLVS), Vaccitech (VACC), KalVista Pharmaceuticals (KALV), Nanobiotix (NBTX), Clene (CLNN), Basilea Pharmaceutica (BPMUF), ZIOPHARM Oncology (ZIOP), Werewolf Therapeutics (HOWL) and SIGA Technologies (SIGA).
View all of ABVC's competitors.

What is ABVC BioPharma's stock symbol?

ABVC BioPharma trades on the OTCMKTS under the ticker symbol "ABVC."

How do I buy shares of ABVC BioPharma?

Shares of ABVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ABVC BioPharma's stock price today?

One share of ABVC stock can currently be purchased for approximately $4.94.

How much money does ABVC BioPharma make?

ABVC BioPharma has a market capitalization of $131.85 million and generates $480,000.00 in revenue each year.

How many employees does ABVC BioPharma have?

ABVC BioPharma employs 30 workers across the globe.

What is ABVC BioPharma's official website?

The official website for ABVC BioPharma is www.ambrivis.com.

Where are ABVC BioPharma's headquarters?

ABVC BioPharma is headquartered at 44370 Old Warm Springs Blvd, Fremont CA, 94538.

How can I contact ABVC BioPharma?

ABVC BioPharma's mailing address is 44370 Old Warm Springs Blvd, Fremont CA, 94538. The company can be reached via phone at 845-291-1291.

This page was last updated on 7/31/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here